Expert Ratings for Astria Therapeutics
Portfolio Pulse from Benzinga Insights
Astria Therapeutics (NASDAQ:ATXS) has received four analyst ratings in the last quarter, all of which are bullish or somewhat bullish. The average price target is $20.25, indicating a significant upside from the current price of $6.4. However, this average has decreased by 14.45% from the previous target of $23.67.
October 13, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astria Therapeutics has received positive analyst ratings, indicating potential upside.
The positive analyst ratings for Astria Therapeutics suggest a bullish outlook for the stock. The average price target of $20.25 is significantly higher than the current price of $6.4, indicating potential for growth. However, the decrease in the average price target could suggest some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100